Developments CRC approves Cohort 2 opening of nimacimab expansion study Skye Biosciences (NASDAQ: SKYE) has announced that the Cohort Review Committee (CRC) has approved opening the second cohort of the CBeyond Part C Expansion study of nimacimab in obesity, based on favorable safety data... May 20, 2026